TherapeuticsMD has filed a registration statement (including a prospectus) with the SEC for the offering to
which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get
these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free 1-866-803-9204.
About
TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The
company is committed to advancing the health of women and championing awareness of their healthcare issues.
Forward Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to,
statements relating to TherapeuticsMDs objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as believes, hopes, may, anticipates, should, intends, plans,
will, expects, estimates, projects, positioned, strategy and similar expressions and are based on assumptions and assessments made in light of managements experience and
perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of
which are outside of the companys control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled Risk
Factors in the companys filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: the companys ability to maintain or increase sales of its products; the companys ability to
develop and commercialize IMVEXXYTM, ANNOVERA, BIJUVATM and its hormone therapy drug
candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could
adversely affect the commercialization of the companys current or future approved products or preclude the approval of the companys future drug candidates; the length, cost and uncertain results of future clinical trials; the
companys reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the companys licensees to commercialize and distribute the companys products; the availability of
reimbursement from government authorities and health insurance companies for the companys products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of
the companys common stock and the concentration of power in its stock ownership. PDF copies of the companys historical press releases and financial tables can be viewed and downloaded at its website:
www.therapeuticsmd.com/pressreleases.aspx.
# # #
Investor Contact
Nichol Ochsner
Vice President Investor Relations
561-961-1900 Ext. 2088
nochsner@TherapeuticsMD.com